ERBB2 and non-small cell lung carcinoma: Also, preclinical data suggest that increased expression of HER3 and NRG1 contribute to resistance to ALK inhibitors.[41–43] Although therapies to block HER2 in NSCLC have had disappointing results in the past, perhaps therapies directed at HRGs, HER3 or HER4 would be more successful.